Question 1

Should I switch from Saxenda to Foundayo?

Accepted Answer

For most adults, Foundayo is the more practical choice — a daily pill with no food restriction, larger expected weight loss (-11.1% in ATTAIN-1 at 17.2 mg vs Saxenda's roughly -8% in SCALE Obesity at 3.0 mg), and a single oral dose form. Switching is straightforward clinically because both are GLP-1 receptor agonists. There is no labeled cross-titration table — most clinicians stop Saxenda and start Foundayo at the 0.8 mg introductory dose, then escalate every 4 weeks. The barriers are practical: Foundayo launches late 2025 to early 2026 with pricing still settling, and any patient who relies on Saxenda for a pediatric or pre-pregnancy reason should not switch.

Question 2

Is the oral pill as effective as the injection?

Accepted Answer

For Foundayo vs Saxenda specifically, the oral pill is more effective. ATTAIN-1 (Wharton 2025 NEJM, PMID 40960239) showed orforglipron 17.2 mg produced -11.1% body-weight reduction at 72 weeks in adults with obesity. SCALE Obesity (Pi-Sunyer 2015 NEJM, PMID 26132939) showed liraglutide 3.0 mg produced approximately -8% at 56 weeks. That is a roughly 3-percentage-point advantage to the pill — driven by Foundayo's higher delivered exposure as a non-peptide small molecule, not by the route. Note this is not a head-to-head trial, so cross-trial comparison carries the usual caveats.

Question 3

Does Foundayo require fasting like Rybelsus?

Accepted Answer

No. This is one of Foundayo's biggest practical advantages over older oral GLP-1 options. Rybelsus (oral semaglutide) requires an empty stomach, a maximum of 4 oz of plain water, and a 30-minute fast before eating, drinking, or taking other oral medications — because semaglutide is a peptide that needs SNAC-assisted absorption through a narrow gastric pH window. Foundayo (orforglipron) is a non-peptide small molecule that is absorbed normally through the gastrointestinal tract. Take it with or without food, at any time of day, with any liquid, per the Foundayo prescribing information.

Question 4

Can children use Foundayo?

Accepted Answer

No. Foundayo is FDA-approved only for adults (18 years and older) for chronic weight management and type 2 diabetes. Saxenda holds the only oral or injectable GLP-1 pediatric obesity indication in the United States, covering adolescents 12 years and older with a body weight above 60 kg and BMI corresponding to obesity in adults. The Ellipse pediatric trial supported that 2020 label expansion. Wegovy was added later for adolescents 12+, but at higher cost. Foundayo's adult-only label means clinicians treating adolescents continue to rely on Saxenda or Wegovy.

Question 5

Why pick Saxenda over Foundayo?

Accepted Answer

Three legitimate reasons remain. First: adolescent patients aged 12 to 17 — Saxenda is the only daily GLP-1 with that pediatric indication. Second: pre-pregnancy planning — liraglutide's roughly 13-hour half-life means full washout in days, while orforglipron's longer pharmacokinetic profile and longer obesity-trial data for any GLP-1 in pregnancy planning give Saxenda a procedural edge for patients trying to conceive within a few months. Third: insurance reality — Saxenda has been on commercial formularies since 2014 and many plans cover it where they will not yet cover the brand-new Foundayo. Outside those three cases, Foundayo's larger magnitude and oral route generally win.

Question 6

How do side effects compare?

Accepted Answer

Both are GLP-1 receptor agonists, so the side-effect profiles are similar and dominated by gastrointestinal events — nausea, diarrhea, vomiting, constipation, decreased appetite, abdominal pain. In SCALE Obesity, nausea ran 39% on liraglutide 3.0 mg vs 14% on placebo. In ATTAIN-1, nausea ran roughly 20-30% on orforglipron 17.2 mg, dose-dependent during titration. Both carry the FDA boxed warning for thyroid C-cell tumors observed in rodents and the standard pancreatitis and gallbladder warnings. The injection route adds injection-site reactions for Saxenda; Foundayo has none. Titrate slowly on either drug to limit GI tolerability problems.

Field	Saxenda	Foundayo
Route	Daily subcutaneous injection (prefilled pen)	Daily oral tablet
Dosing schedule	0.6 -> 1.2 -> 1.8 -> 2.4 -> 3.0 mg daily (5-step weekly titration)	0.8 -> 2.5 -> 5.5 -> 9 -> 14.5 -> 17.2 mg daily (6-step titration)
Mechanism	Peptide GLP-1 receptor agonist	Non-peptide small-molecule GLP-1 receptor agonist
Weight loss (obesity pivotal)	~-8.0% / 56 wk (SCALE Obesity, 3.0 mg)	-11.1% / 72 wk (ATTAIN-1, 17.2 mg)
Head-to-head context (vs Wegovy)	-6.4% at 68 wk (STEP-8, Saxenda 3.0 mg arm)	Not a STEP-8 comparator (Foundayo trials separate)
Food restriction	None — inject any time of day	None — take with or without food, any time of day
FDA-approved indications	Chronic weight management in adults; adolescents 12+ with obesity	Chronic weight management in adults; type 2 diabetes (adults)
Pediatric availability	Approved for adolescents 12 years and older (BMI >=30 adult-equivalent)	Adults only — no pediatric indication
Cash price (US, ~2026)	~$1,400/mo retail; no manufacturer cash-pay program	LillyDirect direct-pay pricing pending at 2026 launch

Saxenda vs Foundayo (2026): Daily Injection vs Daily Pill for Obesity

The verdict

Side-by-side comparison

Frequently asked questions